146 related articles for article (PubMed ID: 17915395)
1. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
2. The learned intermediary doctrine: past, present and future.
Alsobrook HB
Leg Med; 1994; ():269-80. PubMed ID: 7830482
[No Abstract] [Full Text] [Related]
3. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
4. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
5. Evaluating drugs after their approval for clinical use.
Ray WA; Griffin MR; Avorn J
N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
[No Abstract] [Full Text] [Related]
6. Reporting of adverse drug events: a key to postmarketing drug safety.
Rheinstein PH
Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
[No Abstract] [Full Text] [Related]
7. Retesting and laboratory investigations.
Davis JS
J Pharm Sci Technol; 1994; 48(3):107-9. PubMed ID: 8069512
[No Abstract] [Full Text] [Related]
8. [Post-marketing surveillance].
Offerhaus L
Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1201; author reply 1202. PubMed ID: 8692358
[No Abstract] [Full Text] [Related]
9. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
[No Abstract] [Full Text] [Related]
10. Teaching hospitals to track, prevent drug errors.
Koska MT
Hospitals; 1992 Jan; 66(2):69-70. PubMed ID: 1729159
[No Abstract] [Full Text] [Related]
11. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
[No Abstract] [Full Text] [Related]
12. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
13. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
14. FDA's role in drug product recalls.
Crawford SY
Am J Hosp Pharm; 1991 Dec; 48(12):2595-6. PubMed ID: 1814194
[No Abstract] [Full Text] [Related]
15. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
Allan MC
J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug event reporting. Improving the low US reporting rates.
Edlavitch SA
Arch Intern Med; 1988 Jul; 148(7):1499-503. PubMed ID: 3382293
[No Abstract] [Full Text] [Related]
17. Postmarketing surveillance.
Oleen MA
Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
[TBL] [Abstract][Full Text] [Related]
18. The quantification of drug risks in practice.
Lee D; Bergman U
WHO Reg Publ Eur Ser; 1993; 45():79-95. PubMed ID: 8442852
[No Abstract] [Full Text] [Related]
19. Adverse-drug-reaction monitoring.
Faich GA
N Engl J Med; 1986 Jun; 314(24):1589-92. PubMed ID: 3713757
[No Abstract] [Full Text] [Related]
20. FDA puts forth proposal to mandate patient information.
Wechsler J
Formulary; 1995 Oct; 30(10):622-3. PubMed ID: 10151725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
